Clinical trials: Auditory Diseases, Central
- Condition Auditory Diseases, Central
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Malaria, Falciparum
Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function
To evaluate the potential effects of artemether- lumefantrine on the auditory function
- Trial name
- NCT00444106
- Testing
- Artesunate-mefloquine, Atovaquone-proguanil, Artemether-lumefantrine
- Where
- Colombia
- Volunteers
- 265 people
- Sponsor
- Novartis
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat pediatric and adult participants who have severe-to profound and profound hearing loss due to…
- Trial name
- CHORD (NCT05788536)
- Testing
- DB-OTO
- Where
- 17 sites in United States, Germany and 3 more
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Malaria, Falciparum
Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function
THIS STUDY IS NOT ENROLLING PATIENTS IN THE USA. To evaluate the effects of artemether/ lumefantrine on the auditory function.
- Trial name
- NCT00386750
- Testing
- Artemether-lumefantrine
- Volunteers
- 265 people
- Sponsor
- Novartis Pharmaceuticals
Plasmodium Falciparum Malaria
Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria
This study will assess the safety and efficacy of artemether-lumefantrine tablets (6-dose regimen) in African infants / children with acute uncomplicated falciparum malaria.
- Trial name
- NCT00709969
- Testing
- Artemether-lumefantrine
- Where
- 3 sites in Kenya, Nigeria and 1 more
- Volunteers
- 310 people
- Sponsor
- Novartis